300937 Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical
- 21.93
- +0.39+1.81%
Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical News
Pharma Tesco (300937.SZ): Net profit of 9.225 million yuan in the first quarter decreased by 70.84% year-on-year
On April 24, Gelonghui (300937.SZ) released its first quarter report. Operating revenue was 1,237 billion yuan, up 10.29% year on year, net profit was 92.25,500 yuan, down 70.84% year on year. After deducting non-net profit of 6.09 million yuan, down 80.65% year on year, with basic earnings of 0.0964 yuan per share.
Express News | The SPD concept was partially strengthened. First Pharmaceuticals boosted the touchpad, and Medicinal Ecommerce, Heavy Pharmaceutical Holdings, and the opening of the industrial sector followed suit.
Pharmaceutical commercial stocks fluctuated higher, and First Pharmaceutical hit a rise or fall in the afternoon. E-Commerce, Heavy Pharmaceutical Holdings, Kaikai Industrial, Dashenlin, and Yifeng Pharmacy had the highest gains.
Pharmaceutical commercial stocks fluctuated higher, and First Pharmaceutical hit a rise or fall in the afternoon. E-Commerce, Heavy Pharmaceutical Holdings, Kaikai Industrial, Dashenlin, and Yifeng Pharmacy had the highest gains.
Pharma Tesco (300937.SZ): Net profit for 2023 increased by 41.69% to 595.32 million yuan, and plans to pay 10.2.2 yuan
On April 9, Ge Longhui (300937.SZ) announced its 2023 annual report. During the reporting period, the company achieved operating income of 4.430 billion yuan, up 11.62% year on year; net profit attributable to shareholders of listed companies was 595.32 million yuan, up 41.69% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 54.271 million yuan, an increase of 37.40% year on year; basic income per share is 0.62 yuan; it plans to distribute a cash dividend of 2.20 yuan (tax included) for every 10 shares to all shareholders.
Express News | 04/09 08:05:22 [Morning Announcement] ① E-Commerce: The company was originally scheduled to disclose the “2023 Annual Report” and related announcements on April 9. Based on the principle of prudence and a responsible attitude towards investors, in order t
Medicago (300937.SZ): Deferred Disclosure of 2023 Annual Report
Medico-Tesco (300937.SZ) announced that the company was originally scheduled to disclose the “2023 Annual Report” and related announcements on April 9, 2024. In order to ensure the accuracy and completeness of information disclosure, with the approval of the Shenzhen Stock Exchange, the company extended the disclosure period of the “2023 Annual Report” and related announcements until April 10, 2024.
Medicago (300937.SZ): Termination of issuance of shares to specific targets and withdrawal of application documents
On February 23, Ge Longhui (300937.SZ) announced that the company held the 20th meeting of the 3rd board of directors and the 13th meeting of the 3rd board of supervisors on February 22, 2024 to review and pass the “Proposal on Termination of Issuance of Shares to Specific Targets and Withdrawal of Application Documents”. Since the company disclosed its plan to issue shares to specific targets, the company's board of directors, management and relevant intermediaries have been actively promoting various tasks. In view of the current complex and changing market environment and changes in external financing policies, etc., and comprehensively considering many factors such as the company's business development plan and capital operation plan, it is relevant
Medicago (300937.SZ): The ban on 49.3 million shares issued before the initial launch will be lifted on January 29
On January 25, Ge Longhui (300937.SZ) announced an indicative announcement on the listing and circulation of shares issued before the initial public offering. The shares that have been lifted are shares issued by the company before the initial public offering. The number of shares that have been lifted this time is 49.3 million shares, accounting for 51.5331% of the company's total share capital. The listing and circulation date for the shares whose sale restrictions have been lifted is January 29, 2024 (Monday).
Pharmaceutical Easy Purchase (300937.SZ), the supervisor of Tianwen, reduced his holdings by a total of 1,216,800 shares at the end of the reduction period
Pharmaceutical Easy Purchase (300937.SZ) announced that the period of the company's supervisor Tianwen's holdings reduction plan has expired, and through a centralized bidding method...
Pharmaceutical Easy Purchase (300937.SZ): Tianwen reduced its shares by 1.26% by a total of 1.26%
On November 27, Gelonghui (300937.SZ) announced that it recently received the “Notice Letter on Reducing the Shares of Sichuan Hezong Pharmaceutical Co., Ltd. by a total of 1% and the progress of the reduction” issued by Mr. Tian Wenshu, a shareholder holding at least 5% of the company's shares and supervisor. It was learned that Mr. Tian Wenwen reduced his holdings of the company's shares by a total of 1,203,095 shares through centralized bidding between July 19, 2023 and November 24, 2023. The reduction in shareholding accounts for 1.26% of the company's total share capital.
The specific shareholders of Chengdu Boyuan Singapore Airlines and co-actors of Pharmaceutical E-Buy (300937.SZ) reduced their shares by a total of 1.04%
Pharmaceutical Easy Purchase (300937.SZ) issued an announcement. The company recently received the Chengdu Boyuan Singapore Airlines Venture Capital Fund from a specific shareholder...
Pharmaceutical Easy Buy (300937.SZ) plans to increase capital and change its name to Chengdu Pharmaceutical Easy Buy and establish a new subsidiary in Zhengzhou
Pharmaceutical E-Buy (300937.SZ) announcement. The previous announcement revealed that the company plans to establish Sichuan Pharmaceutical E-Buy Technology Group Co., Ltd...
[BT Financial Report Instantaneous Analysis] Pharmaceutical Tesco 2023 Quarterly Report: Net profit has increased dramatically, and the out-of-hospital market has become the main growth point
This financial report was announced on 2023-10-27 19:57:42 Pharmaceutical E-Commerce (stock code: 300937) is an enterprise that plays an important role in the pharmaceutical distribution industry, providing drug sales and distribution services to consumers. As health reform policies deepen and people pay more attention to healthy living, the pharmaceutical distribution market has ushered in new development opportunities. Drug E-Buy plays an important role in this industry, providing drug sales and distribution services to consumers. In terms of assets and liabilities, E-Pharma's total assets for the third quarter of 2023 were 1,625 billion yuan, compared to 15 at the end of the previous year.
Pharmaceutical Easy Buy (300937.SZ) released the first three quarter results, net profit of 50,1573 million yuan, an increase of 198.95%
Pharmaceutical Easy Buy (300937.SZ) released its report for the third quarter of 2023, achieving revenue of 32.1 in the first three quarters...
Tesco (300937. SZ) plans to invest 42 million yuan in the Huzhou Jiansu Pharmaceutical Tesco Fund to lay out major medical and health sectors
Tesco (300937.SZ) announced that the company intends to participate in the Huzhou Jiansu Tesco venture capital as a limited partner...
Tesco (300937.SZ): It is proposed to establish a wholly-owned subsidiary, Sichuan Tesco Technology Group
GLONGHUI, Oct. 13丨Tesco Pharmaceutical (300937.SZ) announced that on October 13, 2023, Sichuan Hezong Pharmaceutical Co., Ltd. held the 15th meeting of the 3rd board of directors to deliberate and pass the “Proposal on Investing in Establishing Wholly-owned Subsidiaries”. The board of directors agreed that the company will jointly invest with its wholly-owned subsidiary Chengdu Heshengyi Technology Co., Ltd. to establish a wholly-owned subsidiary, Sichuan Yaoyisheng Technology Group Co., Ltd., based on the needs of business planning and business development. The registered capital is RMB 1177.77.
Tesco: Some amounts in the company's individual bank accounts have been frozen
GLONGHUI, September 14 | Tesco announced that recently, through bank inquiries, it was learned that the funds in the company's two bank accounts have been frozen. Up to now, the company has not received judicial documents such as court execution rulings. As of the disclosure date of the announcement, the actual amount frozen by the company was 58,194,688.48 yuan, accounting for 7.15% of the company's most recent audited net assets; the maximum amount frozen was 99,294,293.84 yuan, accounting for 12.20% of the company's most recent audited net assets.
The pharmaceutical commercial sector boosted the rise and suspension of Tesco
Gelonghui, August 23 | Tesco rose and stopped by 20cm. Chinese Health, Kaikai Industrial, First Pharmaceutical, Zhejiang Zhenyuan, and Shu Yu Civilian went up one after another.
SPD concept stock boosts Pharmaceutical Tesco by more than 10%
Gelonghui, August 23 | Tesco Pharmaceutical rose more than 10%, followed by Chinese Health, Kaikai Industrial, First Pharmaceutical, Zhejiang Zhenyuan, and Celi Medical.
Changes in A-shares | Tesco surged more than 16%, and medium-term net profit increased more than fivefold year-on-year
Gelonghui, August 23 | Tesco (300937.SZ) has risen sharply by more than 16%. It is currently reported at 3.817 yuan, with a total market value of 3.7 billion yuan. The company announced last night that revenue for the first half of the year was 2.205 billion yuan, an increase of 25.4% over the previous year; Guimu's net profit was 467.177 million yuan, an increase of 540.72% over the previous year. The company continues to expand and optimize various resources and upstream and downstream channels.
Analysis
Price Target
No Data
